X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Unichem Lab with - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs ALKEM LABORATORIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    UNICHEM LAB ALKEM LABORATORIES UNICHEM LAB/
ALKEM LABORATORIES
 
P/E (TTM) x 29.9 - - View Chart
P/BV x 3.1 7.4 42.4% View Chart
Dividend Yield % 0.6 0.6 103.3%  

Financials

 UNICHEM LAB   ALKEM LABORATORIES
EQUITY SHARE DATA
    UNICHEM LAB
Mar-16
ALKEM LABORATORIES
Mar-16
UNICHEM LAB/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3341,589 21.0%   
Low Rs1741,232 14.1%   
Sales per share (Unadj.) Rs146.9417.5 35.2%  
Earnings per share (Unadj.) Rs11.956.3 21.1%  
Cash flow per share (Unadj.) Rs16.264.7 25.0%  
Dividends per share (Unadj.) Rs2.0012.70 15.7%  
Dividend yield (eoy) %0.80.9 87.5%  
Book value per share (Unadj.) Rs105.1292.9 35.9%  
Shares outstanding (eoy) m90.84119.57 76.0%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x1.73.4 51.2%   
Avg P/E ratio x21.425.1 85.2%  
P/CF ratio (eoy) x15.721.8 72.0%  
Price / Book Value ratio x2.44.8 50.2%  
Dividend payout %16.822.6 74.5%   
Avg Mkt Cap Rs m23,073168,653 13.7%   
No. of employees `0005.7NA-   
Total wages/salary Rs m2,5589,171 27.9%   
Avg. sales/employee Rs Th2,352.5NM-  
Avg. wages/employee Rs Th450.9NM-  
Avg. net profit/employee Rs Th190.4NM-  
INCOME DATA
Net Sales Rs m13,34649,915 26.7%  
Other income Rs m1921,645 11.7%   
Total revenues Rs m13,53851,561 26.3%   
Gross profit Rs m1,6398,482 19.3%  
Depreciation Rs m3901,006 38.8%   
Interest Rs m29671 4.3%   
Profit before tax Rs m1,4128,451 16.7%   
Minority Interest Rs m0-114 0.0%   
Prior Period Items Rs m-40-   
Extraordinary Inc (Exp) Rs m-350-   
Tax Rs m2931,606 18.2%   
Profit after tax Rs m1,0806,731 16.1%  
Gross profit margin %12.317.0 72.3%  
Effective tax rate %20.719.0 109.1%   
Net profit margin %8.113.5 60.0%  
BALANCE SHEET DATA
Current assets Rs m5,97927,062 22.1%   
Current liabilities Rs m2,43215,324 15.9%   
Net working cap to sales %26.623.5 113.0%  
Current ratio x2.51.8 139.2%  
Inventory Days Days6367 94.8%  
Debtors Days Days6041 146.3%  
Net fixed assets Rs m6,40312,610 50.8%   
Share capital Rs m182239 76.0%   
"Free" reserves Rs m9,29334,490 26.9%   
Net worth Rs m9,54835,027 27.3%   
Long term debt Rs m2301,212 19.0%   
Total assets Rs m12,84354,387 23.6%  
Interest coverage x50.013.6 367.8%   
Debt to equity ratio x00 69.8%  
Sales to assets ratio x1.00.9 113.2%   
Return on assets %8.613.6 63.5%  
Return on equity %11.319.2 58.9%  
Return on capital %14.324.9 57.7%  
Exports to sales %29.212.9 225.7%   
Imports to sales %6.33.1 205.6%   
Exports (fob) Rs m3,9006,461 60.4%   
Imports (cif) Rs m8471,540 55.0%   
Fx inflow Rs m4,3566,563 66.4%   
Fx outflow Rs m1,1623,012 38.6%   
Net fx Rs m3,1943,552 89.9%   
CASH FLOW
From Operations Rs m1,1197,259 15.4%  
From Investments Rs m-8531,864 -45.8%  
From Financial Activity Rs m-334-9,273 3.6%  
Net Cashflow Rs m-68-150 45.5%  

Share Holding

Indian Promoters % 50.1 66.9 74.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 15.1 33.1 45.6%  
FIIs % 3.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 31.7 0.0 -  
Shareholders   20,176 68,381 29.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare UNICHEM LAB With:   BIOCON LTD  CADILA HEALTHCARE  VENUS REMEDIES  PLETHICO PHARMA  WOCKHARDT LTD.  

Compare UNICHEM LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Feb 23, 2018 (Close)

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB - ELDER PHARMA COMPARISON

COMPARE UNICHEM LAB WITH

MARKET STATS